Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASAFRA:PHS +6.36%80 Intrinsic Value: Projected FCF is €3.26 as of Aug. 18, 2026, which is 100% below its 10-year median of 3.44. GuruFocus rates FRA:PHS with a GF Score™ of 80/100 and a GF Value™ of €6.61 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 631 Drug Manufacturers companies, PhotoCure ASA ranks better than 52.61% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-18), PhotoCure ASA's Intrinsic Value: Projected FCF is €3.26. The stock price of PhotoCure ASA is €5.10. Therefore, PhotoCure ASA's Price-to-Intrinsic-Value-Projected-FCF of today is 1.6.
The historical rank and industry rank for PhotoCure ASA's Intrinsic Value: Projected FCF or its related term are showing as below:
FRA:PHS'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.47 Med: 3.44 Max: 13.78
Current: 1.56
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of PhotoCure ASA was 13.78. The lowest was 1.47. And the median was 3.44.
FRA:PHS's Price-to-Projected-FCF is ranked better than 52.61% of 631
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs FRA:PHS: 1.56
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
PhotoCure ASA's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
5.10
/
3.3197758487631
=
1.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA Intrinsic Value: Projected FCF Related Terms
PhotoCure ASA Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHS vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of €3.26 mean?
PhotoCure ASA (FRA:PHS) has a Intrinsic Value: Projected FCF of €3.26 as of Aug. 18, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on PhotoCure ASA and its competitors. This is near median its historical median of 3.44. Over the past decade, PhotoCure ASA's Intrinsic Value: Projected FCF has ranged from 1.47 to 13.78. According to the industry distribution chart, PhotoCure ASA ranks #299 out of 631 companies in the Drug Manufacturers industry, placing it in the top 47.4%.
Is PhotoCure ASA's Intrinsic Value: Projected FCF too high?
PhotoCure ASA's current Intrinsic Value: Projected FCF of €3.26 is near median its 10-year median of 3.44. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 13.78. Based on the distribution chart, PhotoCure ASA ranks #299 out of 631 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PhotoCure ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #299 out of 631 companies for Intrinsic Value: Projected FCF. This puts PhotoCure ASA in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 1.58. Historically, PhotoCure ASA's own Intrinsic Value: Projected FCF has ranged from 1.47 to 13.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.58, based on 631 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current Intrinsic Value: Projected FCF is €3.26, which is near median its own 10-year median of 3.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.61, compared to a current price of €5.10 — trading 22.8% below its estimated fair value. The current Intrinsic Value: Projected FCF is €3.26, which is near median its 10-year median of 3.44. PhotoCure ASA's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Intrinsic Value: Projected FCF is €3.26 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €5.10 is trading 22.8% below its estimated GF Value™ of €6.61.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
Intrinsic Value: Projected FCF: €3.26 (near median its 10-year median of 3.44)
GF Value™: €6.61 vs. price of €5.10 (22.8% below fair value)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
80GF Score
Get the complete analysis for FRA:PHS
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
